Category Archives: Biologics/Biosimilars

Roche vs Indian Pharma: The battle for a cheaper cancer drug

By Divya Rajagopal, The Economic Times|May 14, 2017 Let’s hark back to the Nineties. The HIV-AIDS epidemic was spreading across Africa, leaving thousands dead, in spite of the existence of anti-retroviral drugs (ARVs). The cost of the treatment, around $10,000, … Continue reading

Posted in Biologics/Biosimilars, Campaign for Affordable Trastuzumab, Cancer, Uncategorized | Leave a comment

Competition Commission of India pulls up Roche for anti-competitive practices

By Jyotsna Singh, Scroll | April 27, 2017 In a landmark order, the commission has initiated an investigation into the multinational pharmaceutical company’s activities. The Competition Commission of India has initiated an investigation into Swiss pharmaceutical giant Roche for unfair … Continue reading

Posted in Biologics/Biosimilars, Campaign for Affordable Trastuzumab, Cancer, Uncategorized | Tagged , , , | Leave a comment

CCI to investigate Swiss drugmaker Roche over breast cancer biosimilar

By Divya Rajagopal, The Economic Times | April 26, 2017 MUMBAI: The Competition Commission of India (CCI) will investigate Swiss drugmaker Roche over alleged attempts to block competitors from selling breast cancer drug Trastuzumab. The investigation has to be completed … Continue reading

Posted in Biologics/Biosimilars, Campaign for Affordable Trastuzumab, Cancer, Uncategorized | Tagged , , , , | Leave a comment

Indian competition commission issues a path breaking order on abuse of dominant position in pharmaceuticals

Rules Roche’s practices prima facie appear to be aimed at blocking affordable biosimilar trastuzumab – a cancer drug – in India In July 2016, Mylan Pharmaceuticals and Biocon Limited approached the Competition Commission of India regarding Roche’s anti-competitive conduct to … Continue reading

Posted in Anti competition, Biologics/Biosimilars, Campaign for Affordable Trastuzumab, Cancer | Tagged , , , , , | Leave a comment

The high price of Big Pharma greed

By Leena Menghaney, The Hindu | March 4, 2017 In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, … Continue reading

Posted in Biologics/Biosimilars, Drug prices, Uncategorized | Tagged , , | Leave a comment

U.S. Supreme Court agrees to hear dispute over biologic drug sales

By Andrew Chung, Reuters The U.S. Supreme Court on Friday agreed to hear a dispute over whether companies that make copycat versions of biologic drugs must wait six months after winning federal approval to begin selling them. The justices will … Continue reading

Posted in Biologics/Biosimilars, Generics, Uncategorized | Leave a comment

Swiss drugmaker Roche launches costliest cancer drugs in India

Economic Times, November 26, 2015. Mumbai: As insurers, patients and governments across the world debate over the rising cost of healthcare, Swiss pharmaceutical major Roche has boldly launched two new drugs for late-stage breast cancer, pricing them higher than any other … Continue reading

Posted in Biologics/Biosimilars, Cancer, Pricing | Leave a comment